Related Experiment Video
Updated: Feb 22, 2026

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
Characterization of the Immune Microenvironment in Hepatocellular Carcinoma
Mark Yarchoan1, Dongmei Xing1, Lan Luan2
1The Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, Maryland.
Insights
Hepatocellular carcinoma (HCC) shows increased expression of inhibitory molecules PD-L1 and LAG-3. This suggests that combining PD-L1 and LAG-3 inhibitors may be a promising immunotherapy strategy for HCC treatment.
Area of Science:
- Oncology
- Immunology
- Hepatology
Background:
- Hepatocellular carcinoma (HCC) frequently develops with chronic liver inflammation.
- Immunotherapies are emerging as potential treatments for HCC.
Purpose of the Study:
- To investigate the immune microenvironment in HCC.
- To analyze the expression of immune checkpoint molecules in HCC tumors.
Main Methods:
- Immunohistochemistry (IHC) was used to assess CD8, PD-1, LAG-3, CD163, and PD-L1 expression.
- Analysis was performed on tumor tissue and liver background from 29 HCC cases.
Main Results:
- CD8 and CD163 expression were reduced in tumor tissues.
- PD-L1 expression was detected in 83% of HCC cases, and LAG-3 in 65%.
- Both PD-L1 and LAG-3 expression were elevated in tumors compared to the liver background.
Conclusions:
- Increased expression of PD-L1 and LAG-3 in HCC suggests their role in T-cell regulation.
- Combinatorial blockade of PD-L1 and LAG-3 presents a potential therapeutic strategy for HCC.
Abstract:
Purpose: Hepatocellular carcinoma (HCC) often arises in the setting of chronic liver inflammation and may be responsive to novel immunotherapies.Experimental Design: To characterize the immune microenvironment in HCC, IHC staining was performed for CD8-positive T lymphocytes, PD-1-positive, and LAG-3-positive lymphocytes, CD163-positive macrophages, and PD-L1 expression in tumor and liver background from 29 cases of resected HCC.Results: Expression of CD8 was reduced in tumor, and expression of CD163 was reduced at the tumor interface. Positive clusters of PD-L1 expression were identified in 24 of 29 cases (83%), and positive expression of LAG-3 on tumor-infiltrating lymphocytes was identified in 19 of 29 cases (65%). The expression of both PD-L1 and LAG-3 was increased in tumor relative to liver background. No association between viral status or other clinicopathologic features and expression of any of the IHC markers investigated was noted.Conclusions: LAG-3 and PD-L1, two inhibitory molecules implicated in CD8 T-cell tolerance, are increased in most HCC tumors, providing a basis for investigating combinatorial checkpoint blockade with a LAG-3 and PD-L1 inhibitor in HCC. Clin Cancer Res; 23(23); 7333-9. ©2017 AACR.
More Related Videos
07:32Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
09:27Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
Published on: April 1, 2021
Related Concept Videos
The Tumor Microenvironment
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...